• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effects of sodium cyanate in mice bearing B16 melanoma.

作者信息

Lea M A, Luke A, Velazquez O, Carpenter L, Martinson C F, Hill H Z, Hill G J

出版信息

Cancer Chemother Pharmacol. 1986;17(3):231-5. doi: 10.1007/BF00256690.

DOI:10.1007/BF00256690
PMID:3742708
Abstract

Sodium cyanate injected IP at a dose level of 200 or 250 mg/kg caused a 90% or greater inhibition of the incorporation of [3H]thymidine into DNA of B16 melanoma transplanted SC in mice. Despite the inhibitory effect of sodium cyanate on precursor incorporation into DNA, no significant effect on host survival was observed when sodium cyanate was administered as a single agent in the diet, in drinking water, or by IP injection to mice that had received IP transplants of B16 melanoma. The action of melphalan and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in prolonging the survival time of melanoma-bearing mice was not enhanced by combined treatment with sodium cyanate. However, combined injections of sodium cyanate and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) increased the survival of tumor-bearing mice significantly more than injections of BCNU alone at a lower dose than the maximum tolerated one. These data and other studies suggest that B16 melanoma may be less responsive to the action of sodium cyanate than are murine leukemic cells or rat hepatomas.

摘要

相似文献

1
Effects of sodium cyanate in mice bearing B16 melanoma.
Cancer Chemother Pharmacol. 1986;17(3):231-5. doi: 10.1007/BF00256690.
2
Alteration of the systemic antitumor activity of melphalan by sodium cyanate in MOPC-460D myeloma-bearing BALB/c mice.氰酸钠对携带MOPC - 460D骨髓瘤的BALB/c小鼠中美法仑全身抗肿瘤活性的影响。
J Surg Oncol. 1993 Feb;52(2):110-4. doi: 10.1002/jso.2930520211.
3
Combined effect of pH and sodium cyanate on the inhibition of tumor cell proliferation and metabolism by BCNU and hyperthermia.pH值和氰酸钠对卡氮芥及热疗抑制肿瘤细胞增殖和代谢的联合作用
Cancer Chemother Pharmacol. 1990;26(4):269-72. doi: 10.1007/BF02897228.
4
THF-gamma 2-mediated reduction of pulmonary metastases and augmentation of immunocompetence in C57BL/6 mice bearing B16-melanoma.
J Immunother. 1999 Mar;22(2):103-13. doi: 10.1097/00002371-199903000-00002.
5
The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.缺氧B16黑色素瘤细胞对化疗药物体内治疗的反应。
Cancer Res. 1975 May;35(5):1147-53.
6
Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy.1-(2-氯乙基)-3-(反式-4-甲基环己基)-1-亚硝基脲作用后宿主组织以及敏感和耐药B16黑色素瘤中DNA合成的抑制与恢复,一种治疗效果的预测指标
Cancer Res. 1975 Sep;35(9):2420-5.
7
Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine.1,3-双(2-氯乙基)-1-亚硝基脲与胸腺嘧啶核苷联合给药的免疫调节及抗肿瘤活性增强作用
Biochem Pharmacol. 1997 Mar 7;53(5):705-13. doi: 10.1016/s0006-2952(96)00905-7.
8
Pharmacokinetics of nitrosoureas: comparison of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) after oral and intravenous administration to rats.亚硝基脲类药物的药代动力学:大鼠口服和静脉注射1,3-双(2-氯乙基)-1-亚硝基脲(卡莫司汀,BCNU)和1-(2-氯乙基)-3-环己基-1-亚硝基脲(洛莫司汀,CCNU)后的比较
Tumori. 1984 Dec 31;70(6):499-502. doi: 10.1177/030089168407000605.
9
Combination chemotherapy against B16 melanoma: bleomycin/vinblastine, bleomycin/cis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU.针对B16黑色素瘤的联合化疗:博来霉素/长春碱、博来霉素/顺二氨二氯铂、5-氟尿嘧啶/卡氮芥以及5-氟尿嘧啶/甲基环己亚硝脲。
Cancer. 1978 Oct;42(4):1711-9. doi: 10.1002/1097-0142(197810)42:4<1711::aid-cncr2820420409>3.0.co;2-x.
10
Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.卡莫司汀(BCNU)与肿瘤坏死因子联合在体外和体内增强抗肿瘤活性。
Br J Cancer. 1990 Nov;62(5):776-80. doi: 10.1038/bjc.1990.378.

引用本文的文献

1
Combined effect of pH and sodium cyanate on the inhibition of tumor cell proliferation and metabolism by BCNU and hyperthermia.pH值和氰酸钠对卡氮芥及热疗抑制肿瘤细胞增殖和代谢的联合作用
Cancer Chemother Pharmacol. 1990;26(4):269-72. doi: 10.1007/BF02897228.

本文引用的文献

1
Some new aspects of mitotic poisoning.有丝分裂中毒的一些新情况。
Nature. 1947 Jun 14;159(4050):794-7. doi: 10.1038/159794a0.
2
Actions of cyanate.氰酸盐的作用。
Br J Pharmacol Chemother. 1946 Sep;1(3):186-93.
3
A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.用于比色法测定脱氧核糖核酸的二苯胺反应的条件及机制研究。
Biochem J. 1956 Feb;62(2):315-23. doi: 10.1042/bj0620315.
4
Effects of cyanate on the distribution of isotope-labeled H2O and extracellular markers in rat liver and tumors.
Cancer Res. 1981 Dec;41(12 Pt 1):4988-92.
5
Inhibition of carcinogen-induced neoplasia by sodium cyanate, tert-butyl isocyanate, and benzyl isothiocyanate administered subsequent to carcinogen exposure.在致癌物暴露后给予氰酸钠、异氰酸叔丁酯和异硫氰酸苄酯对致癌物诱导的肿瘤形成的抑制作用。
Cancer Res. 1981 Aug;41(8):2991-4.
6
Effects of carbamoylation on cell survival and DNA repair in normal human embryo cells (IMR-90) treated with various 1-(2-chloroethyl)-1-nitrosoureas.氨甲酰化对用各种1-(2-氯乙基)-1-亚硝基脲处理的正常人胚胎细胞(IMR-90)的细胞存活和DNA修复的影响。
Cancer Res. 1984 Apr;44(4):1352-7.
7
Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice.
Cancer Chemother Pharmacol. 1984;12(2):94-7. doi: 10.1007/BF00254597.
8
Activation of sodium cyanate for selective inhibition of protein synthesis in cultured tumor cells.氰酸钠激活以选择性抑制培养的肿瘤细胞中的蛋白质合成
Cancer Res. 1981 Jan;41(1):60-6.
9
Sodium cyanate: chemical properties relevant to sickle cell disease therapy.氰酸钠:与镰状细胞病治疗相关的化学性质。
J Pharm Sci. 1973 Oct;62(10):1727-9. doi: 10.1002/jps.2600621038.
10
Dose-response curves after in vivo experimental chemotherapy: influence of route of administration on biological outcomes.
Cancer Chemother Pharmacol. 1985;15(2):91-2. doi: 10.1007/BF00257514.